Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866590 · ClinicalTrials.gov registry record
Pyruvate Kinase Deficiency Epidemiological Study (PIECE)
A clinical trial, sponsored by CENTOGENE GmbH Rostock.
- Completed
- Registry status
- 75
- Enrollment target
NCT03866590 is a clinical trial that has completed, run by CENTOGENE GmbH Rostock. The registered enrollment target is 75 participants.
The verdict
NCT03866590 has completed, sponsored by CENTOGENE GmbH Rostock.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
Pyruvate kinase deficiency (PKD) is the most common red cell glycolytic enzyme defect causing hereditary non-spherocytic hemolytic anemia, caused by mutations in the PKLR gene. The main goal of this study is the diagnosis of pyruvate kinase deficiency in patients who exhibit chronic anaemia and/or splenomegaly and/or judiance and/or hyperbilirubinemia and/or history of prolonged neonatal jaundice and/ or cholelithiasis of undetermined aetiology.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2021-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03866590
The ClinicalTrials.gov registry entry for NCT03866590 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CENTOGENE GmbH Rostock, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03866590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03866590 about?
NCT03866590 is a clinical study titled "Pyruvate Kinase Deficiency Epidemiological Study (PIECE)". Pyruvate kinase deficiency (PKD) is the most common red cell glycolytic enzyme defect causing hereditary non-spherocytic hemolytic anemia, caused by mutations in the PKLR gene. The main goal of this study is the diagnosis of pyruvate kinase deficiency in patients who exhibit chronic anaemia and/or s...
What is the current status of trial NCT03866590?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2020-01-13. Estimated completion is 2021-05-31.
Who is sponsoring clinical trial NCT03866590?
This trial is sponsored by CENTOGENE GmbH Rostock, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.